Facility validation: Theory, practice, and tools

Facility Validation: Theory, Practice, and Tools

Volumn , Issue , 2004, Pages 1-135

  Wrigley, Graham C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39749192083     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (70)

1. World Health Organization (WHO), Essential Drugs and Medicine Policy on Good Manufacturing Practice in Pharmaceutical Production, 2000. Available: http://www.who.int/medicines/organization/qsm/activities/qualityassuran…/orggmp.htm
2. Pharmaceutical Inspection Co-Operation Scheme (PIC/S), Guide to Good Manufacturing Practice for Medicinal Products, PH1/97 (Rev 2), Geneva, August 2001. Available: http://www.picscheme.org
3. European Commission (EC), Guide to Good Manufacturing Practice: Medicinal Products for Human and Veterinary Use, Vol. 4, November 2001. Available: http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm
4. Food and Drug Administration (FDA), Current Good Manufacturing Practice Regulations in Manufacturing, Processing, Packaging or Holding of Drugs (21 CFR Part 210), Rockville, MD, 2001. Available: http://www.cfsan.fda.gov
5. Food and Drug Administration (FDA), Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals (21 CFR Part 211), Rockville, MD, 2001. Available: http://www.cfsan.fda.gov
6. Food and Drug Administration (FDA), Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Rockville, MD, 2001. Available: http://www.cfsan.fda.gov
7. International Conference on Harmonisation (ICH), Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Step 4), ICH Expert Working Group, 2000. Available: http://www.ich.org/
8. Health Canada (HC), Good Manufacturing Practice Guidelines, 2002 ed. Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut.
9. Food and Drug Administration (FDA), Federal Food, Drug, and Cosmetic Act, 1999. Available: http://www.fda.gov/opacom/laws/fdcact/fdctoc.htm
10. Willig, S.H. and Stoker, J.R., Good Manufacturing Practice for Pharmaceuticals: A Plan for Total Quality Control, 4th ed., Marcel Dekker, New York, 1997.
11. Health Canada (HC), Validation Guidelines for Pharmaceutical Dosage Forms, Therapeutic Products Programme, Ontario, 2000 Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut.
12. Barr, D.B., Celeste, A.C., Fish, R.C., and Schwemer, W., Application of pharmaceutical cGMPs, Food and Drug Law Institute (FDLI), Washington D.C., 1997.
13. Medicines Control Agency (MCA), Glossary, in Rules and Guidance for Pharmaceutical Manufacturers and Distributors, The Stationery OfÞce, London, 1997.
14. Food and Drug Administration (FDA), Electronic Records, Electronic Signatures (21 CFR Part 11), Rockville, MD, 2002. Available: http://www.cfsan.fda.gov
15. Pharmaceutical Inspection Co-Operation Scheme (PIC/S), Recommendations on validation master plan, installation and operational qualiÞcation, nonsterile process validation, cleaning validation, PH 006-1, Geneva, 2001. Available: http://www.picscheme.org
16. Food and Drug Administration (FDA), Guidelines on general principles of process validation, Rockville, MD, 1987. Available: http://www.fda.gov/cder/guidance/pv.htm
17. Health Canada (HC), Cleaning Validation Guidelines, Therapeutic Products Programme Ontario, 2000. Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut
18. Health Canada (HC), Process Validation: Aseptic Processes for Pharmaceuticals, 2001. Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut
19. Health Canada (HC), Validation Documentation Requirements and Responsibilities for Drug Fabricators, Packagers/Labelers, Distributors and Importers, July 2001. Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut
20. Lee, J.Y., Recent trends in process validation, in Pharmaceutical Process Validation, Marcel Dekker, New York, 1993.
21. Food and Drug Administration (FDA), Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach, 2002. Available: http://www.fda.gov/oc/guidance/gmp.html
22. Wechsler, J., Washington report: Changes and challenges for CDER, J. Pharm. Technol., August 2001.
23. Pharmaceutical Inspection Co-Operation Scheme (PIC/S), Guide to Good Manufacturing Practice for Medicinal Products, PE 009-1 (Rev 2), Geneva, September 1, 2003. Available: http://www.picscheme.org
24. Jeater, J.P., Cullen, L.F., and Papariello, G.J., Organizing for validation, in Pharmaceutical Process Validation, 2nd ed., Berry, I.R. and Nash, R.A., Eds., Marcel Dekker, New York, 1993.
25. International Society for Pharmaceutical Engineering (ISPE), V-model for indirect impact systems, in Commissioning and QualiÞcation Baseline® Pharmaceutical Engineering Guide, Vol. 5, 1st ed., March 2001.
26. International Society for Pharmaceutical Engineering (ISPE), V-model for direct impact systems, in Commissioning and QualiÞcation Baseline® Pharmaceutical Engineering Guide, Vol. 5, 1st ed., March 2001.
27. Signore, A.A., Good commissioning practices: Strategic opportunities for pharmaceutical manufacturing, J. Pharm. Eng., 57, May/June, 1999.
28. International Society for Pharmaceutical Engineering (ISPE), Commissioning and QualiÞcation Baseline® Pharmaceutical Engineering Guide, Vol. 5, 1st ed., March 2001.
29. Food and Drug Administration (FDA), Guideline on general principles of process validation, Rockville, MD, 1987. Available: http://www.fda.gov/cder/guidance/pv.htm
30. Pharmaceutical Inspection Co-Operation Scheme (PIC/S), Recommendations on validation master plan, installation and operational qualiÞcation, non-sterile process validation, cleaning validation, PH 006-1, Geneva, 2001. Available: http://www.picscheme.org
31. Powell-Evans, K., Validation management and cost control, Ph.D. thesis, University of Brighton, U.K., 2001.
32. International Society for Pharmaceutical Engineering (ISPE) San Francisco Bay chapter, Streamlining validation, J. Pharm. Eng., Jan/Feb, 1998.
33. Davis, J.R. and Hawkins, J.L., II, The validation professional’s survival kit, J. Validation Technol., 4(2), Feb, 1998.
34. James, P., Integrated validation: A way of streamlining projects to reduce project validation time and cost, J. Pharm. Eng., Jan/Feb, 1998.
35. Odum, J.N., The integration of design, construction, and validation: Solving a validation challenge, J. Biopharm., Nov, 1998.
36. Amer, G., Critical documentation requirements in validation, in Introduction to Validation from A to Z – The Ultimate Beginners’ Guide, Institute of Validation Technology, Royal Palm Beach, FL, 2001, p. 112.
37. Flaherty, W.T., Facility validation: management issues, J. Validation Technol., 2(3), Mar, 1996.
38. Stotz, R.W., Controlling the high cost of validation, J. Validation Technol., 3(2), Feb, 1997.
39. Hargroves, J., Cost-effective approaches to validation, J. Validation Technol., 3(2), Feb, 1997.
40. Angelucci, L.A., Master planning — how to get started, J. Validation Technol., 3(2), Feb, 1997.
41. Radich, R. and Lam, J., Eliminating validation management by crisis: Planning for validation using a living master plan, in Introduction to Validation from A to Z – The Ultimate Beginners’ Guide, Institute of Validation Technology, Royal Palm Beach, FL, 2001, p. 55.
42. Wheeler, W.P., Commissioning: A vital precursor to validation, J. Pharm. Eng., Jul/Aug, 1994.
43. International Society for Pharmaceutical Engineering (ISPE), Baseline® Engineering Guide. Commissioning and QualiÞcation, Vol. 5, 1st ed., Tampa, FL, March, 2001, pp. 35–37, 43–44, 53.
44. Angelucci, L.A., Validation and commissioning, J. Pharm. Eng., Jan/Feb, 1998.
45. Castilla, B. and Sena, F.J., Validation documentation: A winning approach, J. Validation Technol., 7(2), Feb, 1997.
46. Chase, R.B. and Aquilano, N.J., Production and Operations Management: A Life Cycle Approach, 6th ed., Irwin, Boston, MA, 1992, p. 884.
47. Gloystein, L., Protocol structure and IQ/OQ costs, J. Validation Technol., 3(2), (Feb), 1997.
48. Odum, J.N., The integration of design, construction, and validation: Solving a validation challenge, J. Biopharm., Nov, 1998.
49. Signore, A.A., Good commissioning practices: Strategic opportunities for pharmaceutical manufacturing, J. Pharm. Eng., May/Jun, 1999.
50. Flaherty, W.T., Facility validation: Management issues, J. Validation Technol., 2(3), March, 1996.
51. International Society for Pharmaceutical Engineering (ISPE), Baseline Engineering Guide. Commissioning and QualiÞcation, Vol. 5, 1st ed., ISPE, March 2001.
52. International Conference on Harmonisation (ICH), Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Step 4), ICH Expert Working Group, 2000. Available: http://www.ich.org/
53. Institute of Validation Technology, The Validation Dictionary, Royal Palm Beach, FL, 2001.
54. Pharmaceutical Manufacturers Association (PMA) of South Africa, Guide to Good Manufacturing Practice, Pretoria, 1996.
55. Food and Drug Administration (FDA), Glossary of computerized system and software development terminology, Rockville, MD, 1995. Available: http://www.fda.gov/ora/inspect_ref/igs/gloss.html
56. Medicines Control Agency (MCA), Glossary, in Rules and Guidance for Pharmaceutical Manufacturers and Distributors, The Stationary OfÞce, London, 1997.
57. International Society for Pharmaceutical Engineering (ISPE), Baseline Engineering Guide. Oral Solid Dosage Forms, Vol. 2, 1st ed., ISPE, February 1998.
58. Gibson, W. and Powell-Evans, K., Validation Fundamentals — How to, What to, When to Validate, Interpharm Press, East Englewood, CA, 1998, pp. 152–156.
59. European Commission (EC), Final version of Annex 15 to the EU Guide to Good Manufacturing Practice Guide to Good Manufacturing Practices, Brussels, EC Working Party on Control of Medicines and Inspections, July 2001. Available: http://pharmacos. eudra.org/F2/eudralex/vol-4/home.htm
60. Pharmaceutical Inspection Co-Operation Scheme (PIC/S), Guide to Good Manufacturing Practice for Medicinal Products, PH1/97 (Rev 2), Geneva, PIC/S, 2001. Available: http://www.picscheme.org
61. National Institute of Building Sciences, Total building commissioning general principles and procedures, Washington, D.C., 1998. Available: http://edesign.state.ß.us/fdi/edesign/resource/totalbcx/guidemod/docs/01nov98.html
62. Food and Drug Administration (FDA), Current Good Manufacturing Practice Regulations in Manufacturing, Processing, Packing or Holding of Drugs (21 CFR Part 210), Rockville, MD, 2001. Available: http://www.cfsan.fda.gov
63. World Health Organization (WHO), Essential Drugs and Medicine Policy on Good Manufacturing Practice in Pharmaceutical Production, 2000. Available: http://www.who.int/medicines/organization/qsm/activities/qualityassuran…/orggmp.htm
64. Warner-Lambert Company, cGMP Orientation Guide, Morris Plains, NJ, 1994.
65. Food and Drug Administration (FDA), Hazard Analysis and Critical Control Point Principles and Application Guidelines, Rockville, MD, 1997. Available: http://www.cfsan.fda.gov/~comm/nacmcfp.html
66. Oxford English Dictionary (OED), The Concise Oxford Dictionary of Current English, Clarendon Press, Oxford, 1976.
67. Pharmaceutical Inspection Co-operation Scheme (PIC/S), Recommendations on validation master plan, installation and operational qualiÞcation, nonsterile process validation, cleaning validation, PH 006-1, Geneva, PIC/S, 2001. Available: http://www.picscheme.org
68. Food and Drug Administration (FDA), Guideline on general principles of process validation, Rockville, MD, 1987. Available: http://www.fda.gov/cder/guidance/pv.htm
69. Pharmaceutical Manufacturers’ Association (PMA) of South Africa, Glossary, in Guide to Good Manufacturing Practice, Pretoria, 1996.
70. Health Canada (HC), Validation guidelines for pharmaceutical dosage forms, Therapeutic Products Programme, Ontario, 2000. Available: http://www.hc-sc.gc.ca/hpb-dgps/therapeut